CollabRx and CellNetix Partner to Advance Molecular Testing in Oncology

CollabRx, Inc. (NASDAQ: CLRX) and CellNetix Pathology & Laboratories, LLC, have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by CellNetix.

Under the terms of the agreement, CollabRx medical and scientific knowledge will be incorporated into the results of genetic sequencing-based tests in oncology provided by CellNetix. CellNetix will leverage CollabRx´s dynamically updated knowledgebase in molecular medicine, ensuring that the latest medical and scientific data is made available to ordering physicians to aid in their interpretation of test results and inform patient treatment planning. CollabRx´s knowledgebase includes the clinical impact of specific genetic profiles and is supported by its large and growing network of over 75 leading clinical practitioners in the US and Europe.

CollabRx is a recognized leader in cloud-based expert systems to inform healthcare decision-making. More information may be obtained at http://www.collabrx.com.

CellNetix Pathology & Laboratories, LLC is a dynamic, rapidly growing private pathology company headquartered in Seattle, Washington. More information may be obtained at http://www.cellnetix.com and at http://www.paml.com.

0saves
If you enjoyed this post, please consider leaving a comment or subscribing to the RSS feed to have future articles delivered to your feed reader.

Leave a Comment

Powered by WordPress